3 articles
Cardiff Oncology's pivotal trial for RAS-mutated metastatic colorectal cancer may fail to meet FDA endpoints when data drops in Q1 2026. CEO Mark Erlander oversees a development program facing potential regulatory rejection that could eliminate the market approval pathway. The medium-likelihood, catastrophic-severity risk arrives as oncology biotechs face heightened FDA scrutiny.
Key Tronic Corp. faces a catastrophic liquidity assessment combining compressed gross margins with severe equity value destruction. The electronics manufacturer's deteriorating market capitalization now flags bankruptcy risk with 70% confidence. Traders are monitoring the situation as a potential harbinger for reshoring-focused manufacturing plays.
Nvidia reports earnings February 25, creating a critical test for semiconductor supply chain stocks exposed to AI infrastructure demand. Aehr Test Systems holds $31M cash but posted $1.3M Q2 loss amid 27% revenue decline, while forecasting $60M-$80M bookings tied to AI chip testing demand. The earnings event will validate whether supply chain players from advanced packaging to data center connectivity can sustain growth narratives.